AtheroMed has started to enrol patients for a clinical trial of its Phoenix atherectomy catheter, a device to treat peripheral arterial disease in the legs.

The FDA-approved investigational device exemption clinical trial will evaluate the safety and effectiveness of the catheter, and will involve 90 patients across 20 clinical sites.

The Phoenix Atherectomy catheter will enable surgeons to cut, capture and pass the arterial plaque into an external bag.

The device is front-cutting and has a deflectable tip which enables the treatment of range of blood vessels sizes.

AtheroMed president and CEO Will McGuire said the catheter had been developed to provide physicians with a safe, versatile, easy to use alternative for treating peripheral arterial disease in the legs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData